Global Information Lookup Global Information

Tafasitamab information


Tafasitamab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD19
Clinical data
Trade namesMonjuvi, Minjuvi
Other namestafasitamab-cxix, MOR208, Xmab5574
AHFS/Drugs.comMonograph
License data
  • US DailyMed: Tafasitamab
Pregnancy
category
  • AU: C[1]
Routes of
administration
Intravenous
ATC code
  • L01FX12 (WHO)
Legal status
Legal status
  • AU: S4 (Prescription only)[2][3]
  • CA: ℞-only / Schedule D[4]
  • US: ℞-only[5]
  • EU: Rx-only[6]
Identifiers
CAS Number
  • 1422527-84-1
DrugBank
  • DB15044
UNII
  • QQA9MLH692
KEGG
  • D11601
Chemical and physical data
FormulaC6550H10092N1724O2048S52
Molar mass147425.93 g·mol−1

Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[5]

Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby.[7] The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite.[7]

Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody.[5][8]

Tafasitamab was approved for medical use in the United States in July 2020,[7][8][9] and in the European Union in August 2021.[6][10] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[11]

  1. ^ "Minjuvi". Therapeutic Goods Administration (TGA). 3 July 2023. Archived from the original on 8 November 2023. Retrieved 10 September 2023.
  2. ^ "Minjuvi (Specialised Therapeutics Alim Pty Ltd)". Therapeutic Goods Administration (TGA). 28 July 2023. Archived from the original on 11 September 2023. Retrieved 10 September 2023.
  3. ^ https://www.tga.gov.au/resources/auspar/auspar-minjuvi
  4. ^ "Summary Basis of Decision (SBD) for Minjuvi". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
  5. ^ a b c "Monjuvi- tafasitamab-cxix injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 12 January 2021. Retrieved 17 January 2021.
  6. ^ a b "Minjuvi EPAR". European Medicines Agency. 23 June 2021. Archived from the original on 22 September 2021. Retrieved 29 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. ^ a b c "Drug Trial Snapshots: Monjuvi". U.S. Food and Drug Administration (FDA). 31 July 2020. Archived from the original on 22 December 2020. Retrieved 17 January 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  8. ^ a b "FDA Approves Monjuvi (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)" (Press release). MorphoSys AG. 31 July 2020. Archived from the original on 2 August 2020. Retrieved 31 July 2020 – via Business Wire.
  9. ^ "Drug Approval Package: Monjuvi". U.S. Food and Drug Administration (FDA). 27 August 2020. Archived from the original on 5 March 2021. Retrieved 18 January 2021.
  10. ^ "Minjuvi Product information". Union Register of medicinal products. Archived from the original on 4 March 2023. Retrieved 3 March 2023.
  11. ^ "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Archived from the original on 18 January 2021. Retrieved 17 January 2021.

and 8 Related for: Tafasitamab information

Request time (Page generated in 0.5274 seconds.)

Tafasitamab

Last Update:

Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory...

Word Count : 676

Incyte

Last Update:

license agreement for the global development and commercialization of tafasitamab with MorphoSys. On March 3, 2020, the agreement received antitrust clearance...

Word Count : 763

MorphoSys

Last Update:

review for tafasitamab, setting a Prescription Drug User Fee Act (PDUFA) goal date of August 30, 2020. On July 31, 2020, Monjuvi (tafasitamab-cxix) was...

Word Count : 1363

Elranatamab

Last Update:

Retifanlimab Sabatolimab Sacituzumab govitecan Serplulimab Sugemalimab Tafasitamab Talquetamab Tarlatamab Teclistamab Tislelizumab Tisotumab vedotin Toripalimab...

Word Count : 760

List of drugs granted breakthrough therapy designation

Last Update:

spectrum disorder Fostemsavir Viiv Healthcare multidrug-resistant HIV-1 Tafasitamab-cxix MorphoSys relapsed or refractory diffuse large B-cell lymphoma Esketamine...

Word Count : 180

Mosunetuzumab

Last Update:

Retifanlimab Sabatolimab Sacituzumab govitecan Serplulimab Sugemalimab Tafasitamab Talquetamab Tarlatamab Teclistamab Tislelizumab Tisotumab vedotin Toripalimab...

Word Count : 758

ATC code L01

Last Update:

L01FX09 Mogamulizumab L01FX10 Olaratumab L01FX11 Bermekimab L01FX12 Tafasitamab L01FX13 Enfortumab vedotin L01FX14 Polatuzumab vedotin L01FX15 Belantamab...

Word Count : 877

Gilles Salles

Last Update:

lymphoma, including rituximab, obinutuzumab, idelalisib, tisagenlecleucel, tafasitamab, tazemetostat. Salles is the author of more than 450 international publications...

Word Count : 1550

PDF Search Engine © AllGlobal.net